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Abstract
Background: Since the beginning of the twentieth century, infection has emerged as a fundamental aspect of
cancer causation with a growing number of pathogens recognized as oncogenic. Meanwhile, oncolytic viruses have
also attracted considerable interest as possible agents of tumor destruction.
Discussion: Lost in the dichotomy between oncogenic and oncolytic agents, the indirect influence of infectious
organisms on carcinogenesis has been largely unexplored. We describe the various ways – from functional aspects
to evolutionary considerations such as modernity mismatches – by which infectious organisms could interfere with
oncogenic processes through immunity. Finally, we discuss how acknowledging these interactions might impact
public health approaches and suggest new guidelines for therapeutic and preventive strategies both at individual
and population levels.
Summary: Infectious organisms, that are not oncogenic neither oncolytic, may play a significant role in
carcinogenesis, suggesting the need to increase our knowledge about immune interactions between infections and
cancer.
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Background
Since the beginning of the twentieth century, accumulat-
ing evidence shows that some infections may be directly
linked to cancer incidence. First, a growing number of
pathogens are recognized to be oncogenic, i.e. infection
is a prerequisite for maintaining or initiating the growth
of cancer cells (Table 1) [1]. Identification of infectious
agents that contribute to oncogenesis, i.e. transformation
of normal cells into cancer cells, constitutes a priority
for cancer prevention mainly because effective prevent-
ive measures exist for some of them [2]. Second, oncoly-
tic pathogens, that selectively destroy tumor tissue, have
also been studied for more than a century as experimen-
tal agents for eliminating cancer cells (Table 2) [3].
One alternative and underexplored way to study the
relationship between infections and oncogenic events is
to investigate the indirect role of infectious organisms1
(i.e., viruses, bacteria, fungi, protozoans and metazoans
that exploit other organisms, called hosts, to complete
their life cycle) that are not considered to be oncogenic
or oncolytic in carcinogenesis. These links may result
from interactions between immune pathways involved in
protection against infectious agents and cancer cells. As
the immune system plays a critical role in the control
and suppression of malignant cells through immunosur-
veillance [4], any disequilibrium in immune system
homeostasis may enhance or constrain cancer cell prolif-
eration. In addition, infectious organisms could interfere
with transmission of oncogenic agents2 through partial
cross-immunity or immune facilitation, a phenomenon
increasingly documented between non-oncogenic patho-
gens [5, 6]. Therefore, we suggest that oncogenic and
oncolytic agents represent the two extremes of a con-
tinuum of organisms that play an indirect role during
oncogenesis. Since infectious organisms are ubiquitous
[7] and co-infections through the course of life remains
the norm rather than exception [8], it calls for an urgent
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need to understand how pathogen communities may
prevent or exacerbate carcinogenesis.
Discussion
Responses of immune system against proliferation of
cancer cells and infections
While the complex links between the immune system
and cancer have been already fully described else-
where [9–11], it is nevertheless worth pointing out
the primary immune mechanisms involved both in infec-
tion process and cancerogenesis. For instance, it has been
shown that cancer cells are able to evade immune system
through numerous mechanisms in advanced stages of
tumor [4, 12]. Therefore, we could assume that infections
may have a significant role at the beginning of carcino-
genesis, i.e. during immunosurveillance. The immune
recognition of specific antigens expressed by cancer cells,
called tumor-associated antigens (TAA), is a necessary
first step to initiate an anti-tumoral response. Receptors
expressed on antigen-presenting cells bind and present
TAA to T helper (Th) lymphocytes in the lymph nodes.
Such Th1-polarized lymphocytes activate cytotoxic T
cells and macrophages which in turn destroy cancer cells.
In agreement with this, a Th1-polarized response has
been mainly recognized to be protective against several
cancers [13, 14]. Finally, to avoid auto-immunity and
chronic inflammation regulatory T cells (Treg) and other
Table 1 Principal oncogenic agents and their participation to associated cancers
Oncogenic agents Associated cancer Contribution Transmission Prevention or elimination
methods
Carcinogens
classification
Ref
Macro-Parasites [90, 91]
Schistosoma haematobium Bladder cancer 30% Water Anti-helminthics
Indirect
Opisthorchis viverrini and
Clonorchis sinensis
Cholangioma liver
cancer
15% Food Anti-helminthics
Bacteria
Helicobacter pylori Stomach cancer 80% Water, sanitation,
food, saliva
Antibiotics, sanitation Indirect [92, 93]
Viruses [92, 94, 95]
Epstein Barr Virus Burkitt’s lymphoma,
nasoparyngeal cancer
10–30% Saliva Antivirals for some
illnesses
Hepatitis B and C Liver cancer 80% needles, sex Vaccination (HBV),
antivirals, blood screening
Human T lymphotropic virus Adult T cell leukaemia Almost 100% Sex, needle, milk No treatment Direct and indirect
Human Papillomavirus Cervical cancer 100% Sex, saliva Vaccination, pap smear
Human Herpesvirus 8 Kaposi sarcoma Almost 100% Sex, saliva No treatment
Merkel cell polyomavirus Merkel cell cancer Almost 100% Saliva No treatment
Today, the World Health Organization acknowledges that at least 20% of cancers have an infectious origin [96]. For transmission section,
“needles” includes blood transfusion, contaminated medical syringes and illicit intravenous drug use. A classification of oncogenic organisms
has been proposed on the basis of their contribution to carcinogenesis [1]. When infection leads to introduction of viral oncogenes into the
host genome, pathogens are considered to be direct carcinogens. These pathogens exploit the host in ways that interfere with mechanisms
of cancer prevention (cell cycle arrest, apoptosis, restriction of telomerase and cell adhesion). Infectious organisms that induce
immunosuppression, chronic inflammation and/or chromosomal instability, are referred to as indirect carcinogens as they may drive mutations
and promote cancer cell proliferation
Table 2 Oncolytic agents
More than a century ago, observations revealed that certain natural viral
infections (e.g., West Nile virus and mumps virus) were associated with
spontaneous cancer remissions [3]. These viruses were subsequently
shown to have a natural preference for cancer cells and infection
with these oncolytic viruses (OVs) triggers lysis of infected cells as well
as activation of anti-tumoral immunity [97]. Advances in molecular
biology have also allowed the modification of other viruses to make
them specific to neoplastic tissues and/or to combined them with
immune reagents to break tumor-induced immune tolerance [98]. For
instance, recombinant measles viruses have been used to treat human
patients with bone-marrow cancer [36]. Interestingly, this treatment only
led to a significant resolution of tumor in two patients who were
measles-seronegative. Recently, a genetically engineered virus called
T-VEC virus has been approved by the US Food and Drug Administration
to treat advanced melanoma [99].
Several studies have also focused on biological anticancer agents based
on oncolytic bacteria. In 2014, Roberts and colleagues tested the
oncolytic potential of Clostridium novyi, a bacterium extremely sensitive
to oxygen that permits the specific targeting of cancer cells, in the
center of solid tumor, that are in a hypoxic environment [100]. A
derivative of the wild-type strain (C. novyi-NT) has been engineered to
become inoffensive for the host [101] and tested via intratumoral
injection against natural canine tumors as well as on advanced
leiomyosarcoma in human patients [102]. C. novyi-NT destroys cancer
cells, but also induces a rapid and robust local antitumoral response.
Such experiments pave the way for considering pathogens as new
therapeutic opportunities to eradicate neoplastic tissues.
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immunosuppressive cells are recruited at the tumor site.
Without ignoring that the immune phenotype of an indi-
vidual results from complex interactions between cellular
and humoral effectors, we suggest that mounting an im-
mune response against invading infectious agents could
interfere with anti-tumoral protection (Fig. 1).
Indeed, several lines of evidence back up this hypoth-
esis. First, the presence of antibodies against TAA has
been observed in cancer-free patients [15], and it has
been suggested that some pathogens might have epi-
topes sharing common features with TAA. In this case,
infection with pathogens expressing TAA might play the
role of priming the immune response and improve, con-
comitantly or on a longer time scale, the effectiveness of
immunosurveillance. Different infectious agents are
known to selectively polarize the immune system to-
wards a Th1 or a Th2 response. Given the reciprocal in-
hibition between Th1 and Th2 effectors [16], the nature
of the infections can have a profound effect on the elim-
ination of cancer cells by immune effectors. This idea is
supported by the finding that patients with a Th2-
polarized immune response have poor prognosis when
suffering from lung, breast, colorectal, pancreatic can-
cers [17]. Finally, responses against extracellular bacteria
and fungi could increase cancer risk through a Th17-
mediated inflammation that may also inhibit resolution
of inflammation by Fox P3 regulatory T cells (Treg) [18].
As humans are usually exposed to a variety of infec-
tious agents during their lives, it could be expected that
the chronology and typology of infections we face, from
childhood to old age, might not only shape the function-
ing of our immune system but also our susceptibility to
cancer. Here, we would like to stress that infections are
likely to interfere with cancer dynamics at the individual
scale depending on i) the personal history of infection
(because of the shared immune responses to cancer cells
and infections), and ii) the interactions between species
within the pathogen communities; but also at the popu-
lation scale depending on iii) the mismatches3 between
the environment experienced by our ancestors and our
current one (Additional file 1: Figure S1). Finally, we will
discuss the possible public health consequences of
underestimating such indirect interactions and call for a
more integrative view of infectious disease control and
cancer prevention strategies.
Personal history of infection can interfere with
destruction of cancer cells
The community of organisms which have infected an in-
dividual during its life represents the personal history of
Th1
Treg
Th 17
Th2
Tumor
Immature 
DC
Immature CD4
IL-12
IFN
TAA
CTL
Antigenic 
presentation
1
Immune 
cascade  
2
Inflammation 
resolution
3
Migration
Infected cell
TAA-like
Latent viruses
Helminths
Bacteria
Fungi
Fig. 1 Shared immune responses to infections and cancer cells. The immune system’s action on cancer cells relies on three main steps: antigenic
presentation, immune cascades and inflammation resolution. Infected cells can express TAA-like antigen which will activate DC subset. DC will
prime Th cells to differentiate into Th1 cells. However, latent viruses and helminths could polarize Th cells toward a Th2 response. Finally, bacterial
and fungal infections could disequilibrate inflammation resolution by activating Th17 cells that down-regulate Treg cells. (DC: dendritic cells; TAA:
tumor associated antigens; Th: T helper cell; CTL: cytotoxic T cells, Treg: regulatory T cells; IFNγ: interferon γ; IL: interleukin)
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infection. Accumulating evidence suggests that taking
into account the past occurrence of infection is import-
ant for a better understanding of cancer epidemiology
(Fig. 2).
Infections occur as early as the first year of life and
may impact the immune system and cancer risk. The
increase in antigenic exposure, after birth through
viral/bacterial infections, may be essential for new-
borns to switch from a Th2 biased [19] to a balanced
Th1/Th2 immunity as well as to develop immuno-
logical memory [20]. Also, childhood diseases may ac-
tivate specific anti-tumoral responses. For instance,
mumps may lead to immune recognition of TAA
present on ovarian cancer cells, resulting in an effect-
ive immunosurveillance [21]. However, childhood dis-
eases could be associated with inflammation, and the
persistence of this inflammatory process in adulthood
may increase the risk of mutations in normal cells,
giving an example of antagonistic pleiotropy4. In fact,
individuals that have experienced major childhood ill-
ness are twice at risk to develop a cancer [22].
Leukemia is a specific example where childhood in-
fections seem to play an ambiguous role [23]. A pro-
tective role of infections was first suggested by
observational studies for Acute Lymphoid Leukemia
(ALL) [24] and has recently been supported by an
epidemiological study for Chronic Lymphoid
Leukemia (CLL) [25]. However, another study has re-
ported that the probability of developing ALL
increases with the number of infectious diseases en-
countered in the first year of life [26].
Infection occurring later in life could also have a
significant impact on the capacity of the immune sys-
tem to keep in check cancer cells. Indeed, protection
against lung cancer has been observed in humans fre-
quently exposed to cattle in the dairy industry [27]. It
has been suggested that protection is provided by en-
dotoxins present in the dust which are known to be
potent immune stimulating factors [28]. Furthermore,
in a lung-cancer model, mice infected with influenza
virus were better able to challenge the tumor [29]. It
was suggested that influenza viruses might produce
TAA which induces immune memory providing life-
long immunosurveillance to cancer cells. The role of
respiratory tract infection has also been highlighted
by a significant positive association between personal
history of pneumonia and CLL risk [30, 31]. Lastly,
personal history of infection may also help to explain
age-related immunodeficiency, i.e., immunosenescence
[32], which is correlated with the reduced capacity to
eliminate cancer cells [33]. By increasing exposure to
antigens, a longer lifespan may induce chronic low-grade
inflammation, contributing to immune disorders, which
may, in turn, lead to accumulation of cancer cells in older
individuals [34].
Acknowledging the role of personal history of in-
fection in cancer initiation and progression might
improve cancer prevention, for instance, through
Fig. 2 Indirect links between cancer and infections across human life. Green boxes and red boxes represent beneficial and detrimental links
respectively. Childhood diseases and infection events occurring during the life of an individual could reduce cancer risk as they may enhance
immune efficiency to eliminate cancer cells. In addition, some vaccines and treatments against infectious diseases have been reported to reduce
cancer risk through the activation of anti-tumoral immunity. At the opposite end of the spectrum, infections may create inflammation or im-
munosuppression episodes that allow cancer cells to proliferate. Finally, chronic exposure to infections could account for age-related immune dis-
orders and the inability to eliminate cancer cells
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prophylactic cancer vaccination [35]. Consideration
of personal infection history could also be useful in
treatment strategies as it could alter patient response
to therapy. For instance, Russell et al. [36] showed
that injection of attenuated measles virus could treat
bone-marrow cancer only if patients have never been
infected by the virus in the past [36]. This result
suggests that immune stimulation may not be high
enough when the patient has already been infected
by the virus and that the decision to use oncolytic
viruses as therapeutic agents has to be made based
on the personal history of infection.
Finally, personal history of infection may be related to
the personal history of medications and vaccination.
Medications that ameliorate symptoms of infection
(fever, headache…) may influence carcinogenesis, as is
the case for anti-inflammatory drugs. Daily consumption
of aspirin, for example, has been recognized to decrease
cancer mortality, in part by inhibiting metastasis [37].
Second, medications could be used against specific infec-
tious agents. For instance, the anti-malarial artesunate
shows an anti-tumoral activity comparable to other can-
cer drugs [38]. Also, a range of antibiotics disrupting
mitochondrial functions have also been reported to
eradicate stem cells of different tumor types [39]. Finally,
vaccination against specific infectious agents could be
used to prevent cancer. In fact, several studies report
protection against melanoma, lymphoma or leukemia
after BCG, vaccinia or yellow fever vaccination [40, 41].
These findings might be explained by non-specific ef-
fects of vaccines through the shifting of the immune re-
sponse towards a Th1 profile or through cross reactivity
[42]. Vaccines may also contain pathogen antigens with
amino-acid sequences that are homologous with those
of certain TAA [43]. By this cross reaction effect, vaccin-
ation allows eliminating malignant cells as soon as they
appear. For instance, a prior immunization with BCG
vaccine, which has antigenic similarity with human en-
dogenous retroviruses (HERV-K-MEL), expressed in 95%
of malignant melanocytes, has been associated with bet-
ter survival in patients with melanoma [44].
Infectious organisms can modify transmission of
oncogenic agents
While many pathogens can alter anti-tumoral immunity,
some infections can also influence transmission of onco-
genic pathogens. Indeed, as with any free organisms,
species that form pathogen communities do interact in a
synergistic or antagonistic ways [45], with effects on the
epidemiology of each species within the community. On
non-oncogenic pathogens, it has been shown, for in-
stance, that HIV is responsible for a 37-fold increase in
the risk to contract tuberculosis [46] whereas convales-
cence period induced by measles impacts the dynamics
of the epidemic of Bordetella pertussis (the causative
agent of a whooping cough) [47]. Here, we suggest that
this type of interactions has the potential to influence
cancer epidemiology by altering the transmission of
oncogenic agents.
Endemic Burkitt Lymphoma has been associated with
Epstein-Barr Virus infection in infancy and is geograph-
ically linked to holoendemic Plasmodium falciparum
[48]. This association may result from reciprocal benefits
for the two species (Fig. 3a). On the one hand, P. falcip-
arum antigens can directly induce EBV reactivation and
decrease EBV-specific T-cells during malaria infection
[49, 50]. On the other hand, EBV in the lytic cycle is as-
sociated with suppressed B-cells [51] which play a role
in the control of P. falciparum [52].
Second, human papillomavirus (HPV) persistence is
the major cause of cervical cancer. Epidemiological stud-
ies have shown that Chlamydia trachomatis infection is
also associated with this cancer [53] and increases the
risk for persistence of HPV infection [54]. One potential
mechanism of this interaction may rely on C. trachoma-
tis products which may impact immunity allowing the
oncogenic agent to persist. In fact, Chlamydia infection
induces COX2 protein expression in epithelial cells and
promotes PGE2 release [55]. PGE2 has been identified
to down-regulate IL-12 production and the antigen-pre-
senting function of dendritic cells [56]. Therefore, C.
trachomatis infection may increase transmission of
HPV by inhibiting cell-mediated immunity but also
by creating a pro-inflammatory environment [57] fa-
vorable to HPV persistence (Fig. 3b).
Third, Schistosoma haematobium, an African trematode
that has recently spread into Mediterranean Europe [58],
is associated with urinary bladder cancer [59]. Interest-
ingly, several studies have reported a high percentage of
bacterial co-infection in the urinary tract [60, 61]. This
pattern can be explained by the fact that helminths can in-
duce an impairment of NKT cells promoting bacterial in-
fections [62]. However, bacterial infections of the urinary
tract have also been reported to increase the risk of blad-
der cancer through the production of nitrosamines, which
are carcinogenic compounds [63]. Therefore S. haemato-
bium could have two facilitating roles in carcinogenesis: a
direct role through inflammation-induced DNA damages
[64] and an indirect role in immune facilitation (Fig. 3c).
In addition to these well-described examples, evidence
of interactions between infectious organisms and onco-
genic agents are accumulating for other co-occurrences.
For instance, co-infection with Hepatitis C virus (HCV),
the causative agent of liver cancer, and Schistosoma
mansoni has been linked to an increase in viral persist-
ence [65]. In the presence of HCV, S. mansoni has been
shown to alter the CD4+ T cell proliferative response to-
ward a Th2 profile [66], preventing the HCV-specific
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Th1 response and thus its elimination (Fig. 3d). Specific
interactions through the immune system may also occur
in the following co-infections: HHV8/Mansonella per-
stans [67] and Merkel cell virus/Pseudomonas aerugi-
nosa [68], however, the mechanisms have not been fully
identified yet.
Finally, all interactions described above are associated
with an increase in persistence/transmission of oncogenic
agents while examples of co-infection conferring protec-
tion are scarce. We suggest that protection might come
from co-infection involving closely related pathogenic spe-
cies. For example, the immune response against Helico-
bacter pylori (stomach cancer) and H. bilis (biliary tract
cancer [69]) may be very similar [70], and cross-immunity
could result in reciprocal protection. The same mechan-
ism could be applied to co-infections with varicella and
HHV8 and/or EBV as they all belong to the Herpesvirus
genus for which type I interferon plays a central role [71].
Infectious organisms and cancer susceptibility:
an evolutionary perspective
Throughout evolutionary history, humans have been ex-
posed to a great diversity of infectious agents, and the
composition of the community has also fluctuated
greatly over time [72]. In wealthy countries, mankind
has experienced a significant decrease in infectious pres-
sures due to public health strategies, including antibi-
otics, vaccines, and improved sanitation. The reduced
prevalence of infectious diseases has however been
paralleled by an increased incidence of many immune
disorders, inflammatory diseases, and cancers. One evo-
lutionary hypothesis relies on the mismatch that has rap-
idly (within a century) occurred between our current
infectious environment and the one that our ancestors
have been exposed to for thousands of years [73].
Infections could drive carcinogenesis by trade-offs5 at
individual and population scales
The idea that cancer might result from antagonistic plei-
otropy (improving early survival and/or reproduction at
the expenses of late fitness6 (Additional file 1: Fig. S1)) is
currently considered to be a viable hypothesis [74].
Nevertheless, very few studies have explored whether
traits that help to limit the cost of infection might pro-
mote carcinogenesis later in life.
More specifically, resistance against infections could
impact pro-oncogenic inflammation. The early immune
response to infection relies on acute inflammation [75]
A
B
C
D
Fig. 3 Interactions between infectious agents and oncogenic agents. a Reciprocal benefits between Epstein Barr Virus (EBV) and Plasmodium
falciparum. While EBV suppresses B cells involved in the control of P. falciparum, the latter one induces EBV reactivation and decreases EBV-
specific T-cells. b Helper function of Chlamydia trachomatis toward human papillomavirus. C. trachomatis products decrease antigenic presenta-
tion by dendritic cells allowing the oncogenic agent to persist. c Interactions between Schistosoma haematobium and bacteria. S. haematobium
induces the impairment of NKT cells promoting bacterial infections of the urinary tract. d Co-infection with Hepatitis C virus (HCV) and Schisto-
soma mansoni. In the presence of HCV, S. mansoni has been shown to alter the CD4+ T cell proliferative response toward a Th2 profile, preventing
the elimination of the virus by specific Th1 response
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which is also accepted as a hallmark of cancer [12]. Des-
pite these oncogenic consequences, the inflammatory re-
sponse still confers a fitness benefit in environments
with high infectious burdens, because it improves the
survival prospect at early life. Accordingly, fast-paced
species rely more on pro-inflammatory responses
whereas slow-paced species tend more toward anti-
inflammatory responses [76]. In pathogen-rich environ-
ments, pro-inflammatory genes could have been favored,
as fitness benefits that arise from early protection against
infection would be greater than fitness costs arising later
in life, like increased risk of cancer. Pro-inflammatory
genes that have been positively selected during human
evolutionary history may now be involved in the in-
creased incidence of cancers in modern environments
with reduced pathogen loads.
An example of such mismatch comes from the relative
vulnerability of African Americans to malignant diseases
compared with people of Caucasian origins in the USA
[77]. Relocation of Africans from tropical countries,
where pro-tumoral inflammation following Th2 activa-
tion was beneficial, into North America, and the conse-
quent change in infection risk, may expose them to a
higher risk of cancer [78]. Thus, the eradication of some
infectious agents – notably those that co-evolved with
us – may drive the vulnerability to immune-related dis-
orders, with consequences for cancer susceptibility.
While the use of helminths, or at least their immuno-
modulatory products, has been suggested in treatments
of some inflammatory disorders [79], we hypothesize
that they could reduce pro-tumoral inflammation, thus
pro-tumoral mutation and accumulation of cancer cells.
A caveat for such arguments derives from the fact that
helminths, like other infectious organisms, evolve char-
acteristics that enhance their own fitness; it is, therefore,
naïve to expect that they could have uniformly positive
immunological effects on human chronic diseases. If hel-
minths, by their immunoregulatory role, suppress in-
flammation, they could reduce inflammation-induced
oncogenesis. If, however, persistent infection by hel-
minths generates a net increase in inflammation, they
could contribute to oncogenesis, an effect that occurs in
trematode-associated bladder cancer and cholangiocarci-
noma [80].
Long-term co-evolution and persistence of oncogenic
agents
From an evolutionary perspective, interactions between
oncogenic agents and non-oncogenic infectious agents
are of considerable importance for understanding the
dynamics of co-evolution among geographically struc-
tured populations evolving under different ecological
pressures. When an infectious agent is detrimental to
host fitness, selection should favor resistance genes.
However, when infections result in net fitness advan-
tages, susceptibility genes should be maintained in the
host population. For example, it has recently been sug-
gested that H. pylori confers protection against tubercu-
losis (a lethal disease without appropriate medication)
through enhancing IFNγ and Th1-like response to spe-
cific tuberculosis antigens [81]. In areas where tubercu-
losis is highly prevalent, susceptibility to H. pylori might
have been favored by natural selection (Fig. 4). These
conflicting selection pressures could potentially explain
the wide distribution of H. pylori. Since 1950’s, antibi-
otics and vaccines have dramatically decreased tubercu-
losis prevalence in developed countries [82], suggesting
that host resistance against H. pylori could be selected.
Nevertheless, the appearance of resistant strains of M.
tuberculosis in these populations combined with the in-
crease of HIV transmission could together maintain sus-
ceptibility to H. pylori. Finally, in countries with low
parasite pressure, the persistence of H. pylori could also
be explained by its protective role against another cancer
as it has been reported that elimination of the bacterium
comes with an increase in esophageal adenocarcinoma
incidence [83].
Conclusion
In this paper, we put forward several arguments suggest-
ing that the links between infectious organisms and car-
cinogenesis through the immune system are varied and
complex, and cannot be restricted to the study of onco-
genic and oncolytic agents. These interactions can
operate over the short-term through an altered immuno-
surveillance (Table 3 summarizes such examples when
proximal mechanism has been identified) or via antag-
onistic/synergistic interactions between oncogenic and
non-oncogenic agents, but also on a long-term leading
to mismatches. Our arguments stress the need to
broaden the view on the interactions between infections
and oncogenesis. The interactions, described here to give
a glimpse of the overall complexity, also include the
microbiota and its possible role on carcinogenesis [84].
Therefore, rather than just studying a simple interaction
between one individual and its cancer, we need to ex-
plore the intimate connections that could exist with its
symbionts sensu largo in a given environment.
From an applied perspective, the stimulation of the
immune system is a promising way to target cancer
cells without damaging the healthy ones [85]. Most
studies have focused on the relationship between im-
munity and cancer cells elimination based on the un-
derstanding of immunological mechanisms underlying
the dialog between T-helper cells. Specific antibodies
blocking CTLA-4 function enhance T-cell stimulation
and promote anti-tumor immunity [86]. T-cell therap-
ies, e.g., those using tumor-infiltrating lymphocytes
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(TIL) and chimeric antigen receptors (CAR), are
promising [87]. Similarly, antibodies have been engi-
neered to block the action of the Th17 cell subset,
which secretes interleukin 17, with consistent results
in mice where antibody injection was followed by a
decrease in the number of tumors [88]. In this paper,
we suggest that personal history of infection/medica-
tion, including childhood diseases, could modify how
the immune system responds to immunotherapy pos-
sibly altering its efficiency.
The increase in cancer prevalence has been associ-
ated with lifestyle changes, such as an increased cal-
oric intake, urbanization, and sedentary habits [89].
However, infection prophylaxis, improved medicine,
and sanitation can also modify the strength of the in-
teractions between infectious agents. In this context, the
impact of infectious disease control on cancer epidemi-
ology must be considered. Further work should focus on
the potential effect of infectious organisms on cancer inci-
dence and the consequences of infectious disease
Table 3 Examples of indirect interactions between infectious organisms and cancer through immunity for which the exact
mechanism has been identified.TNF (Tumor Necrosis Factor)
Impact on cancer Infectious organisms Mechanism implied Immune
compartment
Cancers References
Exacerbating Human Immunodeficiency
virus
Destruction of CD4 + T cells CD4+ T cells Several cancers (including
those with infectious origin)
[103–106]
Fusobacterium nucleatum
(intra-tumoral bacteria)
Inhibition by contact between
bacterial Fap2 protein and immune
cell receptor TIGIT
Natural Killer cells Various tumors [107]
Cytomegalovirus (infecting
cancer cells)
Secretion of immunoregulatory
protein (cmvIL-10)
Dentritic cells Gliomas [108, 109]
Constraining Streptococcus pyogenes/ Serratia
marcescens
Secretion of high quantity of TNF Global immune
system
Sarcoma [110, 111]
Attenuated Bacillus
Calmette-Guérin (BCG)
Local stimulation of CD4+ T cells
and Th1 immune response.
Diminution of Treg cells.
T cell subsets Bladder cancer [112, 113]
Fig. 4 Long term interaction between Mycobacterium tuberculosis and Helicobacter pylori. H. pylori confers protection against M. tuberculosis
through an increase in IFN production. In countries with a high prevalence of tuberculosis, infection with H. pylori might confer a selective benefit
allowing the maintenance of H. pylori susceptibility genes
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treatments on cancer risk at different scales. Such a global
perspective is indispensable to anticipate the possible con-
sequences of our current public health strategies.
Endnotes
1Infectious organisms: organisms that live obligatorily
at the expense of another organism, called the host. The
relation is beneficial for the infectious agent but detri-
mental for the host. This broad definition includes path-
ogens (virus, bacteria, fungi) and parasites (protozoans,
helminthes, ticks among others).
2Oncogenic agents: Infectious organisms recognized to
have a direct and significant contribution to carcinogen-
esis. At the opposite, we refer to non-oncogenic agents
when there is no direct evidence for a contribution in
tumoral process.
3Mismatches between genotype and environment arise
when a phenotype or genotype that were selected in a
particular context (e.g. in a high parasitic burden) be-
comes detrimental in a new environment.
4Antagonistic pleiotropy describes a situation where
particular genes (e.g. inflammatory genes) have opposite
effects on fitness at different ages, such that their effects
are beneficial in early life, when natural selection is
strong (following infections for instance), but harmful at
later ages, when selection weakens.
5Trade-off: balance between the cost and the benefit
of biological mechanisms regarding the fitness of the or-
ganism. It underlies that both aspects compete for a
common resource.
6Fitness: capacity of an individual to produce viable
offspring, in other words contribution of an individual to
the future generation. Also described as lifetime repro-
ductive success.
Additional file
Additional file 1: Figure S1. Antagonistic pleiotropy and mismatch
concept. Antagonistic pleiotropy describes a situation where particular
genes (e.g. inflammatory genes) have opposite effects on fitness at
different ages, such that their effects are beneficial in early life, when
natural selection is strong (following infections for instance), but harmful
at later ages, when selection weakens. Whereas, mismatches between
genotype and environment arise when a phenotype or genotype that
were selected in a particular context (e.g. in a high parasitic burden)
becomes detrimental in a new environment. (PPT 239 kb)
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